A process for producing a metal-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a metal source to provide a metal-Mo composition. The metal-Mo composition can be pH adjusted with a base to precipitate a plurality of metal-Mo particulates.

This document provides methods and materials for using live transgenic non-human animals (e.g., non-human mammals) to perform radiotracer imaging to monitor pathological processes, disease progression, or therapeutic responses in vivo over time. For example, methods and materials for using live transgenic non-human animals (e.g., non-human mammals) having somatic and germline cells that include nucleic acid (e.g., a transgene) having a promoter sequence operably linked to a nucleic acid sequence encoding a NIS polypeptide to perform radiotracer imaging to monitor pathological processes, disease progression, or therapeutic responses in vivo over time are provided.

A radiotherapy source for treating a tumor, which includes a flexible core impermeable to radon and a polymer coating on the flexible core. The polymer coating is impermeable to radium, and allows diffusion of radon therethrough. The radiotherapy source also includes alpha-emitting radium radionuclides in the polymer coating or between the flexible core and the polymer coating.

Provided are methods to treat cancer, in which (1) a patient is first identified as having a cancer that is likely to be susceptible to gallium therapy, by the use of a gallium scan or other procedure that shows whether the cancer is gallium-avid, and (2) the patient is then treated with a pharmaceutically acceptable gallium composition.

In one aspect, radioactive nanoparticles are described herein. In some embodiments, a radioactive nanoparticle described herein comprises a metal nanoparticle core, an outer metal shell disposed over the metal nanoparticle core, and a metallic radioisotope disposed within the metal nanoparticle core or within the outer metal shell. In some cases, the radioactive nanoparticle has a size of about 30-500 nm in three dimensions. In addition, in some embodiments, the radioactive nanoparticle further comprises an inner metal shell disposed between the metal nanoparticle core and the outer metal shell. The metal nanoparticle core, outer metal shell, and inner metal shell of the radioactive nanoparticle can have various metallic compositions.

This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging.

Structure and luminescence properties of a new Cu-Cyteamine (Cu-Cy) crystal material are provided. The crystal structure of the Cu-Cy is determined by single crystal X-ray diffraction. It is found that the compound crystallizes in the monoclinic space group C2/c and cell parameters are a=7.5510(4) , b=16.9848(7) , c=7.8364(4) , =104.798(3). The new Cu-Cy crystal material of the invention is also useful for treatment of cancer.

Described herein are methods for quantifying skeletal muscle perfusion, skeletal muscle metabolism, and active vascular calcification by positron emission tomography (PET) imaging of labeled radionuclides, such as .sup.18F-labeled radionuclide agents.

This invention relates to low density radioactive magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging.

A SPECT diagnostic method of performing myocardial perfusion imaging on a patient, the method comprising the steps of: administering a rest radiotracer to the patient while the patient is at rest; scanning the heart of the patient, with the patient positioned at a scanning position, to obtain a rest perfusion image; administering a stressing agent to the patient to place the patient's heart under stress; administering a stress radiotracer while the heart of the patient is under stress; scanning the heart to obtain a stress perfusion image; maintaining the patient at the scanning position from the commencement of the rest perfusion image through the completion of the stress perfusion image.